AIM ImmunoTech Statistics
Total Valuation
AIM ImmunoTech has a market cap or net worth of $4.21 million. The enterprise value is $6.03 million.
Important Dates
The last earnings date was Friday, March 27, 2026, before market open.
| Earnings Date | Mar 27, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
AIM ImmunoTech has 8.15 million shares outstanding. The number of shares has increased by 188.95% in one year.
| Current Share Class | 8.15M |
| Shares Outstanding | 8.15M |
| Shares Change (YoY) | +188.95% |
| Shares Change (QoQ) | +37.65% |
| Owned by Insiders (%) | 1.95% |
| Owned by Institutions (%) | 1.71% |
| Float | 7.99M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 47.53 |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 68.55 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.53
| Current Ratio | 0.53 |
| Quick Ratio | 0.49 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -14.36 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -101.32% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 2,638.91% |
| Weighted Average Cost of Capital (WACC) | 12.47% |
| Revenue Per Employee | $4,190 |
| Profits Per Employee | -$664,667 |
| Employee Count | 21 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -85.65% in the last 52 weeks. The beta is 1.36, so AIM ImmunoTech's price volatility has been higher than the market average.
| Beta (5Y) | 1.36 |
| 52-Week Price Change | -85.65% |
| 50-Day Moving Average | 0.76 |
| 200-Day Moving Average | 2.15 |
| Relative Strength Index (RSI) | 39.23 |
| Average Volume (20 Days) | 326,230 |
Short Selling Information
The latest short interest is 159,719, so 1.96% of the outstanding shares have been sold short.
| Short Interest | 159,719 |
| Short Previous Month | 94,590 |
| Short % of Shares Out | 1.96% |
| Short % of Float | 2.00% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, AIM ImmunoTech had revenue of $88,000 and -$13.96 million in losses. Loss per share was -$8.62.
| Revenue | 88,000 |
| Gross Profit | -40,000 |
| Operating Income | -11.66M |
| Pretax Income | -13.96M |
| Net Income | -13.96M |
| EBITDA | -11.45M |
| EBIT | -11.66M |
| Loss Per Share | -$8.62 |
Full Income StatementBalance Sheet
The company has $3.05 million in cash and $4.90 million in debt, with a net cash position of -$1.85 million or -$0.23 per share.
| Cash & Cash Equivalents | 3.05M |
| Total Debt | 4.90M |
| Net Cash | -1.85M |
| Net Cash Per Share | -$0.23 |
| Equity (Book Value) | -9.78M |
| Book Value Per Share | -3.19 |
| Working Capital | -2.93M |
Full Balance SheetCash Flow
| Operating Cash Flow | -10.96M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | 210,000 |
| Net Borrowing | 2.09M |
| Free Cash Flow | -10.96M |
| FCF Per Share | -$1.34 |
Full Cash Flow StatementMargins
| Gross Margin | -45.45% |
| Operating Margin | -13,254.55% |
| Pretax Margin | -15,861.36% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
AIM ImmunoTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -188.95% |
| Shareholder Yield | -188.95% |
| Earnings Yield | -333.68% |
| FCF Yield | -261.94% |
Analyst Forecast
The average price target for AIM ImmunoTech is $10.00, which is 1,837.61% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $10.00 |
| Price Target Difference | 1,837.61% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | 208.43% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 9, 2026. It was a forward split with a ratio of 1.001:1.
| Last Split Date | Jan 9, 2026 |
| Split Type | Forward |
| Split Ratio | 1.001:1 |
Scores
AIM ImmunoTech has an Altman Z-Score of -113.71 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -113.71 |
| Piotroski F-Score | 3 |
